Neuroprotective Products: World Market Prospects 2012-2022

NEW YORK, July 4, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Neuroprotective Products: World Market Prospects 2012-2022

http://www.reportlinker.com/p0923285/Neuroprotective-Products-World-Market-Prospects-2012-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

Report Details

Your guide to trends and revenue prospects in neuroprotection

What are the commercial prospects for neuroprotective treatments? Visiongain's new report shows you potential revenues and trends to 2022, discussing data, opportunities and outlooks.

Many neuroprotective products are in development. Our study lets you assess projected sales at overall world market, therapeutic submarket and product level to 2022. 

The protection of nerve tissues is becoming more important. You can assess the potential for drug revenues there, as well as finding discussions of stem cells and gene therapy.

In particular, how will 11 products - including Rasagiline, Minocycline, Memantine and NeuroSTAT - perform to 2022? Our investigation gives you business research and analysis with sales forecasts.

You also see forecasting of five world-level submarkets to 2022, finding potential revenues: 

• Ion channel modulators

• Mitochondrial dysfunction regulators

• Anti-inflammatory and anti-apoptotic agents

• Neurotrophic factors

• Other neuroprotective treatments.

Our study lets you assess the R&D pipeline, seeing trends and prospects. You find data and discussions on developmental topics:

• Alzheimer's disease

• Parkinson's disease

• Multiple sclerosis

• Brain injury

• Ocular degeneration (retinal disorders)

• Huntington's disease

• Amyotrophic lateral sclerosis (ALS)

• Neuropathies

• Other disorders affecting the nervous system.

The neuroprotection market offers strong opportunities for medicines to slow disease progression, protecting the central nervous system (CNS). Our report shows and explains.

Market value for 2014 and outlook for the future

What does the future hold? The pharma industry will develop more drugs for neuronal protection, with high revenues possible this decade and beyond. The R&D pipeline is strong and promising. Overall world revenues will reach $2.6bn in 2014, our report forecasts.

We predict that the neuroprotection market will achieve strong revenue growth to 2022, especially from 2017. By then, many clinical trials will have finished and products will gain regulatory approval. You see prospects for novel drugs. 

Rising incidence and prevalence of neurodegenerative diseases in ageing populations will stimulate that treatment market. Also stimulating the industry and market will be the treatment of brain injuries, especially those from traffic accidents.

What are companies doing? Our work discusses Ceregene, Genervon Biopharmaceuticals, Neuren Pharmaceuticals and others, evaluating commercial prospects. The scope of the field is widening, with many organisations entering and collaborating.

The aim of drug developers is to prevent neuronal death and revive damaged neurons (neuroregeneration). However, not all neuroprotective agents will be neuroregenerative, the study predicts.

Regulatory agencies recognise the therapeutic potential of neuroprotective agents and have given fast track designation and orphan drug status to candidates.

You can investigate the future of neuroprotection now, discovering revenue potential and other prospects. 

Sales forecasts, market shares, developmental trends and discussions

In visiongain's report you find revenue forecasting, growth rates and market shares. Also, you see qualitative analyses (SWOT and STEP) and discussions of R&D activities. You receive 46 tables, 22 charts and two research interviews.

Nine ways Neuroprotective Products: World Market Prospects 2012-2022helps you

In particular, our study gives you the following knowledge on the topic:

• Find potential revenues to 2022 for the world market and submarkets

• Discover projected revenue trends of 11 leading products to 2022

• See predictions of launch times for prominent drug candidates

• Assess 7 leading companies, and other players, discovering activities and outlooks

• Review R&D pipelines, seeing trends by therapeutic area and organisation

• Investigate competition and opportunities influencing sales

• Find out what will stimulate and restrain the industry and market

• Analyse prospects for established companies and those seeking to enter the sector

• View opinions from our survey, seeing interviews with authorities in industry.

There, you discover quantitative and qualitative analyses with independent predictions. You receive information that only our report contains, staying informed on business intelligence.

Without our report you could miss out on information that your competitors use.

Gain research and analysis now for neuroprotective treatments 

Our study is for everybody needing industry and market analyses for neuroprotection. You find data, predictions and answers there. Please order that report now.

Visiongain is a trading partner with the US Federal Government

CCR Ref number: KD4R6 

Table of Contents

1. Executive Summary

1.1 Overview of Findings

1.2 Structure of the Report

1.3 Research and Analysis Methods

1.4 Scope of the Report

1.4.1 Inclusions

1.4.2 Exclusions

2. Introduction to Neuroprotection 

2.1 What is Neuroprotection?

2.2 History of Neuroprotective Agents

2.3 Neurodegeneration

2.3.1 Excitotoxicity

2.3.2 Oxidative Stress

2.4 Mechanisms of Neuroprotection 

2.4.1 Ion Channel Modulators

2.4.2 Mitochondrial Dysfunction Regulators

2.4.3 Anti-inflammatory and Anti-apoptotic Agents

2.4.4 Neurotrophic Factors

2.4.5 Other Neuroprotective Agents

2.5 Importance of Neuroprotective Agents

3. World Market for Neuroprotective Agents to 2022 

3.1 Neuroprotective Agents: World Market, 2011

3.2 Neuroprotective Agents: World Market Forecast, 2012-2022 

3.3 Classes of Neuroprotective Agent

3.3.1 Ion Channel Modulators

3.3.1.1 Ion Channel Modulators: Market Forecast, 2011-2012

3.3.2 Mitochondrial Dysfunction Regulators

3.3.2.1 Mitochondrial Dysfunction Regulators: Market Forecast, 2012-2022

3.3.3 Anti-inflammatory and Anti-apoptotic Agents

3.3.3.1 Anti-inflammatory and Anti-apoptotic Agents: Market Forecast, 2012-2022

3.3.4 Neurotrophic Factors

3.3.4.1 Neurotrophic Factors: Market Forecast, 2012-2022

3.3.5 Other Neuroprotective Agents

3.3.5.1 Other Neuroprotective Agents: Market Forecast, 2012-2022

4. Prominent Neuroprotective Agents under Development

4.1 Rasagiline (Teva/Lundbeck) 

4.1.1 Rasagiline is Currently Approved for Parkinson's Disease

4.1.2 Rasagiline as a Neuroprotectant

4.1.3 Rasagiline: Market Potential Analysis, 2012-2022

4.1.4 Competition for Rasagiline

4.2 Minocycline (National Institute of Neurological Disorders and Stroke [NINDS])

4.2.1 Minocycline: Competitor Analysis and Sales Forecast, 2012-2022

4.3 Memantine (Merz/Lundbeck/Forest Laboratories/Daiichi Sankyo)

4.3.1 Memantine: Competitor Analysis and Sales Forecast, 2012-2022

4.4 NeuroSTAT (NeuroVive Pharmaceutical AB)

4.4.1 NeuroSTAT: Competitor Analysis and Sales Forecast, 2012-2022

4.5 Erythropoietin (Various Companies)

4.5.1 EPO: Competitor Analysis and Sales Forecast, 2012-2022

4.6 GM6 (Genervon Biopharmaceuticals)

4.6.1 Current Status of Development

4.6.2 GM6 Sales Forecast, 2012-2022

4.6.3 GM6: Competitors and Risk Analysis

4.7 NNZ-2566 (Neuren Pharmaceuticals)

4.7.1 NNZ-2566: Competitor Analysis and Sales Forecast, 2012-2022

4.8 Progesterone (BHR-100, BHR Pharma LLC)

4.8.1 Progesterone: Competitor Analysis and Sales Forecast, 2012-2022

4.9 Davunetide (Allon Therapeutics)

4.9.1 Davunetide: Competitor Analysis and Sales Forecast, 2012-2022

4.10 Laquinimod (Teva/Active Biotech AB)

4.10.1 Laquinimod: Competitor Analysis and Sales Forecast, 2012-2022

4.11 CXB909 (Krenitsky Pharmaceuticals/CeNeRx BioPharma)

4.11.1 CXB909: Competitor Analysis and Sales Forecast, 2012-2022

5. Leading Organisations in 2012

5.1 Genervon Biopharmaceuticals

5.1.1 Platforms for Drug Discovery and Development

5.1.2 R&D Pipeline Analysis

5.2 Neuren Pharmaceuticals

5.2.1 Market Position and R&D Pipeline

5.2.2 US Army Funding for NNZ-2566

5.3 NeuroVive Pharmaceutical AB

5.3.1 Current Status and R&D Pipeline

5.3.2 Strategic Collaborations

5.4 Allon Therapeutics

5.4.1 Market Status and R&D Pipeline

5.5 Ceregene

5.5.1 Current Status and R&D Pipeline

5.6 BHR Pharma

5.6.1 Current Status and R&D Pipeline

5.7 Varinel

5.7.1 Current Status and R&D Pipeline

5.7.2 Strategic 

Collaborations

5.8 National Institute of Neurological Disorders and Stroke (NINDS)

5.8.1 Research Supported by NINDS 

5.9 Leading Countries in Neuroprotective Research

6. Neuroprotective Agents in Various Pathologies

6.1 Brain Injury

6.1.1 Current Treatment for Brain Injuries

6.1.2 Neuroprotective Agents under Development for Brain Injuries

6.2 Alzheimer's Disease

6.2.1 Limited Number of Drugs Approved for Alzheimer's

6.2.2 Neuroprotective Agents under Development for Alzheimer's Disease

6.3. Parkinson's Disease

6.3.1 Current Therapies for Parkinson's Disease

6.3.2 Neuroprotective Agents under Development for Parkinson's Disease

6.4 Multiple Sclerosis

6.4.1 Current Therapies for Multiple Sclerosis

6.4.2 Neuroprotective Agents under Development for Multiple Sclerosis

6.5 Ocular Degeneration

6.5.1 Current Treatment for Ocular Degeneration

6.5.2 Neuroprotective Agents under Development for Ocular Degeneration

6.6. Other Neurodegenerative Diseases

6.6.1 Huntington's Disease

6.6.1.1 Treatment Options

6.6.2 Amyotrophic Lateral Sclerosis (ALS) 

6.6.2.1 Treatment Options

6.6.3 Neuropathies

6.6.3.1 Neuropathic Pain

6.6.3.2 Treatment Options

6.6.4 Neuroprotective Agents under Development for Other Neurodegenerative Diseases

7. Neuroprotective Agents: Qualitative Industry Analysis 

7.1 Strengths

7.1.1 Neurological Disorders are High Profile

7.1.2 Chronic Diseases: Long-Term Repeat Sale

7.2 Weaknesses

7.2.1 The High Cost of Treatment

7.2.2 Difficulty Generating Ideal Laboratory Models for Neuroprotection

7.2.3 Difficulty in Clinical Trials for Neuroprotection 

7.3 Opportunities

7.3.1 Orphan Status and Fast-Track Reviews for New Drugs

7.3.2 Aging Populations Will Lead to Increased Disease Prevalence

7.3.3 Significant Unmet Needs Exist in the Market

7.3.4 Alternative Treatments Provide Additional Opportunities to the Neuroprotection Industry

7.3.4.1 Stem Cell Therapy

7.3.4.2 Gene Therapy

7.4 Threats

8. Research Interviews

8.1 Interview with Larry Glass, CEO, Neuren Pharmaceuticals (March 2012)

8.1.1 Failure of Clinical Trials Testing Neuroprotective Agents

8.1.2 Agent NNZ-2566

8.1.3 Sub-classes of Neuroprotective Agent

8.1.4 Promising Neuroprotective Agents

8.1.5 Potential of Neuroprotective Agents

8.2 Interview with Winston Ko, CEO, Genervon Biopharmaceuticals (March 2012)

8.2.1 Lack of Approved Neuroprotective Agents

8.2.2 Sub-classes of Neuroprotective Agent

8.2.3 Agent GM6

8.2.4 Promising Neuroprotective Agents

8.2.5 Potential of Neuroprotective Agents

9. Conclusions

9.1 High Demand for Neuroprotective Agents in Medicine 

9.2 Multibillion Dollar Revenues Possible from World Neuroprotection Market

9.3 Strong R&D Pipeline for Neuroprotective Agents

9.4 Rising Disease Prevalence Levels from Aging Populations Will Drive Market Growth

9.5 Going from Pre-clinical Studies into Clinical Testing Will Remain Challenging

9.6 Concluding Remarks

List of Tables

Table 3.1 Neuroprotective Agents: Market Forecast by Drug Categories ($bn), 2011-2022

Table 3.2 Neuroprotective Agents World Market Forecast ($bn), 2011-2022

Table 3.3 Neuroprotective Agents Drug Class: Sales ($bn) & Market Shares (%), 2011

Table 3.4 Neuroprotective Agents Drug Class: Sales ($bn) & Market Shares (%), 2015

Table 3.5 Neuroprotective Agents Drug Class: Sales ($bn) & Market Shares (%), 2022

Table 3.6 Ion Channel Modulators Sales Forecast ($bn), 2011-2022

Table 3.7 Mitochondrial Dysfunction Regulators Sales Forecast ($bn), 2011-2022

Table 3.8 Anti-inflammatory & Anti-apoptotic Agents Forecast ($bn), 2011-2022

Table 3.9 Neurotrophic Factors Forecast ($bn), 2011-2022

Table 3.10 Other Neuroprotective Agents Forecast ($bn), 2011-2022

Table 4.1 Key Neuroprotective Agents: Sales Forecast ($bn), 2011-2022

Table 4.2 Rasagiline Sales Forecast ($bn), 2011-2022

Table 4.3 Studies Investigating Minocycline as a Neuroprotectant

Table 4.4 Minocycline Sales Forecast ($bn), 2011-2022

Table 4.5 Memantine Sales Forecast ($bn), 2011-2022

Table 4.6 NeuroSTAT Sales Forecast ($bn), 2011-2022

Table 4.7 Studies Investigating Erythropoietin as a Neuroprotectant, 2012

Table 4.8 Erythropoietin Sales Forecast ($bn), 2011-2022

Table 4.9 GM6: Preliminary Results, 2012

Table 4.10 GM6 Development, 2012

Table 4.11 GM6 Sales Forecast ($bn), 2011-2022

Table 4.12 NNZ-2566 Sales Forecast ($bn), 2011-2022

Table 4.13 Progesterone Sales Forecast ($bn), 2011-2022

Table 4.14 Davunetide Sales Forecast ($bn), 2011-2022

Table 4.15 Laquinimod Sales Forecast ($bn), 2011-2022

Table 4.16 CXB909 Sales Forecast ($bn), 2011-2022

Table 5.1 Genervon Biopharmaceuticals: R&D Pipeline, 2012

Table 5.2 Neuren Pharmaceuticals: R&D Pipeline, 2012

Table 5.3 NeuroVive Pharmaceutical: R&D Pipeline, 2012

Table 5.4 NeuroVive Pharmaceutical: Strategic Collaborations

Table 5.5 Allon Therapeutics: R&D Pipeline, 2012

Table 5.6 Ceregene: R&D Pipeline, 2012

Table 5.7 BHR Pharma: R&D Pipeline, 2012

Table 5.8 Varinel: R&D Pipeline, 2012

Table 5.9 Varinel: Strategic Collaborations, 2012

Table 5.10 NINDS: Ongoing Clinical Trials, 2012

Table 6.1 Selected Neuroprotective Agents under Investigation for Brain Injury, 2012

Table 6.2 Selected Neuroprotective Agents under Investigation for Alzheimer's Disease, 2012

Table 6.3 Selected Neuroprotective Agents under Investigation for Parkinson's Disease, 2012

Table 6.4 Selected Neuroprotective Agents under Investigation for Multiple Sclerosis, 2012

Table 6.5 Selected Neuroprotective Agents under Investigation for Ocular Degeneration, 2012

Table 6.6 Selected Neuroprotective Agents under Investigation for Other Neurodegenerative Diseases, 2012

Table 7.1 Neuroprotective Agents Market: SWOT Analysis, 2012-2022

Table 7.2 Neuroprotective Agents Market: STEP Analysis, 2012-2022

Table 7.3 Population Proportions (%) Aged Over 65 by Region, 2025 and 2050

Table 9.1 Key Neuroprotective Agents: Sales ($bn) and Market Shares (%), 2022

List of Figures

Figure 3.1 Neuroprotective Agents World Market Forecast ($bn), 2011-2022

Figure 3.2 Neuroprotective Agents Market Shares (%) by Drug Categories, 2011

Figure 3.3 Neuroprotective Agents Market Shares (%) by Drug Categories, 2015

Figure 3.4 Neuroprotective Agents Market Shares (%) by Drug Categories, 2022

Figure 3.5 Ion Channel Modulators Sales Forecast ($bn), 2011-2022

Figure 3.6 Mitochondrial Dysfunction Regulators Sales Forecast ($bn), 2011-2022

Figure 3.7 Anti-inflammatory & Anti-apoptotic Agents Forecast ($bn), 2011-2022

Figure 3.8 Neurotrophic Factors Forecast ($bn), 2011-2022

Figure 3.9 Other Neuroprotective Agents Forecast ($bn), 2011-2022

Figure 4.1 Rasagiline Sales Forecast ($bn), 2011-2022

Figure 4.2 Minocycline Sales Forecast ($bn), 2011-2022

Figure 4.3 Memantine Sales Forecast ($bn), 2011-2022

Figure 4.4 NeuroSTAT Sales Forecast ($bn), 2011-2022

Figure 4.5 Erythropoietin Sales Forecast ($bn), 2011-2022

Figure 4.6 GM6 Sales Forecast ($bn), 2011-2022

Figure 4.7 NNZ-2566 Sales Forecast ($bn), 2011-2022

Figure 4.8 Progesterone Sales Forecast ($bn), 2011-2022

Figure 4.9 Davunetide Sales Forecast ($bn), 2011-2022

Figure 4.10 Laquinimod Sales Forecast ($bn), 2011-2022

Figure 4.11 CXB909 Sales Forecast ($bn), 2011-2022

Figure 7.1 Population Proportions (%) Aged Over 65 by Region, 2025 and 2050

Figure 9.1 Key Neuroprotective Agents: Market Shares (%), 2022 

Companies Listed

Acorda Therapeutics 

Active Biotech AB

Advancell

Albert Einstein College of Medicine of Yeshiva University

Alcon Laboratories

Allergan

Allon Therapeutics

Alta Partners

Alzheimer's Drug Discovery Foundation

Alzheimer's Association

Alzheimer's Disease Cooperative Study (ADCS)

American Brain Injury Consortium (ABIC)

Arbor Vita Corporation

Assistance Publique - Hopitaux de Paris

AstraZeneca

Avraham Pharmaceuticals

Bagcilar Training and Research Hospital

Bastyr University

Bayer

Baylor College of Medicine

Besins Healthcare

BHR Pharma

BioAxone Therapeutic

Biogen Idec

BioSante Pharmaceuticals

Brain Cells

BrainStorm Cell Therapeutics

Buck Institute for Research on Aging 

Buck Institute of Technology

Buddhist Tzu Chi General Hospital

Cantonal Hospital of St. Gallen

CAS Medical Systems

Catholic University of the Sacred Heart

CeNeRx BioPharma

Centre Hospitalier Universitaire de Nice

Ceregene

Charité University

CHDI

Children's Hospital & Research Center Oakland

Children's Hospital of Pittsburgh

China Medical University Hospital

Cornell University

Daiichi Sankyo

Danube Pharmaceuticals

DENSMORE Pharmaceutical

Department of Veterans Affairs

Duke University

El Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez

Eli Lilly

EMD Serono

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

European Brain Injury Consortium

European Cooperative Network for Research, Diagnosis and Therapy of Parkinson's Disease

Eyetech

Food and Drug Administration (US FDA) 

Forest Laboratories

Fundacion para la Investigacion Biomedica del Hospital

Genervon Biopharmaceuticals

GW Pharmaceuticals

Hadassah Medical Organization

Hamilton BioVentures

High Q Foundation

Hoag Memorial Hospital Presbyterian

Huntington Hospital

Huntington Medical Research Institutes

INC Research

Institute for Quality and Efficiency in Health Care (IQWiG)

Investor Growth Capital

Janssen

Jaslok Hospital and Research Centre

Krenitsky Pharmaceuticals

Laerdal Medical

Lundbeck

Max Planck Institute

Medical University of South Carolina

Merz Pharmaceuticals

Michael J. Fox Foundation for Parkinson's Research

Mount Sinai School of Medicine

MPM Capital

Multiple Sclerosis Society of Great Britain and Northern Ireland

Multiple Sclerosis Trust

Mylan

National Center for Complementary and Alternative Medicine (NCCAM)

National Heart, Lung, and Blood Institute (NHLBI)

National Institute for Health and Clinical Excellence (NICE)

National Institute of Neurological Disorders and Stroke (NINDS)

National Institute on Aging (NIA)

National Institutes of Health (NIH)

National Institutes of Health Clinical Center (CC)

National Multiple Sclerosis Society

Neuralstem

Neuregenix

Neuren Pharmaceuticals

Neurological Emergencies Treatment Trials Network (NETT)

Neuroscience Canada

Neurotec Pharma

Neurotech

NeuroVive Pharmaceutical AB

Newron Pharmaceuticals

NoNO

Northwestern University

Novartis

Office of Dietary Supplements (ODS)

Ono Pharmaceutical

Opexa Therapeutics

Oregon Health and Science University

Orion Pharma

Oxygen Biotherapeutics

Pfizer

Pharmanza Herbal

PRA International

Prana Biotechnology

QLT

Quark Pharmaceuticals

Rexahn Pharmaceuticals

Roche

Royan Institute

Rush University Medical Center

S & T Global

Sanofi

Santa Clara Valley Health & Hospital System

Selcia

Shaheed Beheshti Medical University

SK Biopharmaceuticals

StoneBridge Pharma

TCA Cellular Therapy

Technion Medical School

Teva Pharmaceutical Industries

Texas Children's Hospital

The Dana Foundation

Thrasher Research Fund

to-BBB

Toyama Chemical Co.

Universitaria Meyer

Universitaria Pisana

Universitario Ramon y Cajal

University College London

University of Calgary

University of California, Los Angeles

University of California, San Francisco

University of Miami

University of Rochester

University of South Florida

University of Utah

University of Washington

Varinel

Verdure Sciences

U.S. Department of Defense

Watson Pharmaceuticals

World Health Organization (WHO)

Xuanwu Hospital, Beijing

Zambon Company 

To order this report:

Pathology Industry: Neuroprotective Products: World Market Prospects 2012-2022

More  Market Research Report

Check our  Industry Analysis and Insights

Contact Nicolas: [email protected]
US: (805)-652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker